Trials / Completed
CompletedNCT00952198
A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 128 (actual)
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 study, involving a 10-day dosing period, designed to test the safety of investigational study drug ARRY-403 (as monotherapy or in addition to stable metformin therapy) in patients with Type 2 diabetes. Approximately 128 patients from the US will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARRY-403, glucokinase activator; oral | multiple dose, escalating |
| DRUG | Placebo; oral | matching placebo |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2009-08-06
- Last updated
- 2020-10-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00952198. Inclusion in this directory is not an endorsement.